Abstract
Two novel approaches for the development of new drugs against AIDS are summarized each leading to the achievement of important discoveries in anti-HIV therapy. Despite the success of HAART in reducing mortality, resistant strains continue to emerge in the clinic, underscoring the importance of developing next-generation drugs. Protein-protein interactions and human cellular cofactors represent the new targets of tomorrow in HIV research. The most relevant results obtained in the last few years by the two new strategies are described herein.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adaptor Proteins, Signal Transducing / metabolism
-
Anti-HIV Agents / pharmacology
-
Anti-HIV Agents / therapeutic use
-
CD4 Antigens / metabolism
-
DEAD-box RNA Helicases / metabolism
-
HIV Envelope Protein gp120 / metabolism
-
HIV Infections / drug therapy*
-
HIV Infections / metabolism
-
HIV Integrase
-
Humans
-
Protein-Tyrosine Kinases / metabolism
-
Receptors, CCR5 / metabolism
-
Transcription Factors / metabolism
Substances
-
Adaptor Proteins, Signal Transducing
-
Anti-HIV Agents
-
CCR5 protein, human
-
CD4 Antigens
-
HIV Envelope Protein gp120
-
PSIP1 protein, human
-
Receptors, CCR5
-
Transcription Factors
-
gp120 protein, Human immunodeficiency virus 1
-
Protein-Tyrosine Kinases
-
HIV Integrase
-
DDX3X protein, human
-
DEAD-box RNA Helicases
-
p31 integrase protein, Human immunodeficiency virus 1